Tobias Maurer

Learn More
BACKGROUND CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-resistant prostate-cancer. METHODS 44 Patients received up to 5 intra-dermal vaccinations. Three dose levels(More)
Hiermit erkläre ich an Eides statt, dass ich die vorliegende Arbeit selb-stständig verfasst und keine anderen als die angegebenen Quellen und Hilfsmittel verwendet habe. Acknowledgements I would like to express my gratitute to everybody who contributed to this work by ideas and inspiration and thus helped this work to manifest. First of all many thanks to(More)
PURPOSE Transrectal ultrasound (TRUS)-guided random prostate biopsy is, in spite of its low sensitivity, the gold standard for the diagnosis of prostate cancer. The recent advent of PET imaging using a novel dedicated radiotracer, [Formula: see text]-labeled prostate-specific membrane antigen (PSMA), combined with MRI provides improved pre-interventional(More)
BACKGROUND Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting(More)
BACKGROUND Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk(More)
Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with (68)Ga-PSMA ligand Positron emission tomography/computed tomography(More)
PURPOSE Due to the high expression of the integrin αvβ3 not only on endothelial cells, but also on mature osteoclasts and prostate cancer cells, imaging of osseous metastases with αvβ3-targeted tracers seems promising. However, little is known about the patterns of αvβ3-expression in metastasized prostate cancer lesions in-vivo. Thus we evaluated the uptake(More)
Aim of study In patients with prostate cancer increased levels of PSMA can be measured. Recently a new tracer, 68 Ga-PSMA, was developed as a specific marker for hybrid imaging (PET/ CT, MR-PET). In this study we evaluated the accuracy of 68 Ga-PSMA in patients with rising PSA after radical prosa-tectomy, so called " biochemical recurrent prostate cancer "(More)